<DOC>
	<DOCNO>NCT03086486</DOCNO>
	<brief_summary>To evaluate efficacy , safety tolerability various dos duration linezolid plus bedaquiline pretomanid 26 week treatment participant either pulmonary XDR-TB , pre-XDR-TB , treatment intolerant non-responsive MDR-TB .</brief_summary>
	<brief_title>Safety Efficacy Various Doses Treatment Durations Linezolid Plus Bedaquiline Pretomanid Participants With Pulmonary TB , XDR-TB , Pre- XDR-TB Non-responsive/Intolerant MDR-TB ( ZeNiX )</brief_title>
	<detailed_description>A phase 3 , multi-center , partially-blinded , randomized clinical trial four parallel treatment group . Bedaquiline pretomanid treatment blind . Linezolid treatment dose duration double-blinded . Participants screen period 9 day randomize receive one 4 active treatment arm . Participants randomize one four regimens 1:1:1:1 ratio , use interactive web response system ( IWRS ) utilize dynamic randomization system use minimization random element allocate participant evenly across arm HIV status type TB . Each participant receive 26 week treatment . If participant 's week 16 sample remain culture positive , Investigator may consider extend current treatment 39 week , consultation Sponsor Medical Monitor Participants follow 78 week end treatment .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Multidrug-Resistant</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<mesh_term>Extensively Drug-Resistant Tuberculosis</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Bedaquiline</mesh_term>
	<mesh_term>Diarylquinolines</mesh_term>
	<criteria>Participants require meet follow inclusion criterion screen period order randomize . 1 . Provide write , informed consent prior trialrelated procedure ( include additional consent require participant consider minor per applicable regulatory authority ethic committee ) . 2 . Willingness ability attend schedule followup visit undergo study assessment 3 . HIV test ( HIV test perform within 1 month prior screen , repeat long documentation provide [ ELISA and/or Western Blot ] . If HIV status confirm know positive , repeat HIV test need provide documentation available . 4 . Male female , age 14 year old . Disease Characteristics : 5 . Participants one follow pulmonary TB condition : a. XDRTB . A documented culture positive molecular test positive ( MTB ) sputum specimen collect within 3 month prior screen MTB confirm sputum base molecular test within 3 month prior screen : ii . historical document resistance isoniazid , rifamycins , fluoroquinolone AND injectable current TB diagnosis/disease course ; b. PreXDRTB . A documented culture positive molecular test positive ( MTB ) sputum specimen collect within 3 month prior screen MTB confirm sputum base molecular test within 3 month prior screen ; ii . historical document resistance isoniazid , rifamycins , fluoroquinolone OR injectable current TB diagnosis/disease course . c. MDRTB i. document culture positive molecular test positive ( MTB ) sputum specimen collect result within 3 month prior screen MTB confirm sputum base molecular test within 3 month prior screen ; ii . historical document resistance isoniazid rifamycins current TB diagnosis/disease course ; iii . document nonresponse treatment best available regimen 6 month prior enrolment opinion Investigator adherent treatment adherent study regimen . d. MDRTB i. document culture positive molecular test positive ( MTB ) sputum specimen collect within 3 month prior screen MTB confirm sputum base molecular test within 3 month prior screen : ii . historical document resistance isoniazid rifamycins current TB diagnosis/disease course ; iii . unable continue second line drug regimen due document intolerance : 1 . PAS , ethionamide , aminoglycosides fluoroquinolones ; 2 . Current treatment list render participant eligible study Investigator 's opinion . 6 . Chest XRay within one month prior screening , obtain read locally investigator designee result consistent pulmonary TB opinion Investigator . Contraception : 7 . Be nonchildbearing potential use effective method birth control , define : Nonchildbearing potential : 1 . Participant heterosexually active practice sexual abstinence ; 2 . Female participant/sexual partner bilateral oophorectomy , bilateral tubal ligation and/or hysterectomy postmenopausal history menses least 12 consecutive month ; 3 . Male participant/sexual partner vasectomise bilateral orchidectomy least three month prior Screening . Effective birth control method : A double contraceptive method use follow : 1 . Double barrier method include 2 follow : male condom , diaphragm , cervical cap , female condom ( male female condom use together ) ; 2 . Barrier method ( one ) combine hormonebased contraceptive intrauterine device female participant/partner ; And willing continue practice birth control method throughout treatment 6 month ( male female participant ) last dose study medication . Participants exclude participation meet follow criterion screen period : Medical History Concurrent Conditions 1 . Any condition Investigator 's opinion ( i.e. , unstable disease uncontrolled diabetes cardiomyopathy , extrapulmonary TB require extend treatment , cancer could affect survival protocolspecified follow period ) , participation trial would compromise wellbeing participant prevent , limit confound protocol specify assessment . 2 . Abuse alcohol illegal drug opinion Investigator would compromise participant ' safety ability follow protocolspecified restriction , visit evaluation . 3 . In judgment Investigator , patient expect survive 6 month . 4 . Karnofsky score &lt; 60 screening . 5 . History allergy know hypersensitivity trial Investigational Medicinal Products related substance . 6 . Body mass index ( BMI ) &lt; 17 kg/m2 7 . TB infection know resistance pretomanid , delamanid , linezolid bedaquiline . 8 . Participants , upon evaluation pulmonary disease , expect require surgical procedure . 9 . Having participate clinical study dose investigational agent within 8 week prior screen currently enrol investigational study include treatment medicinal agent . Participants participate observational study follow period trial include drug therapy may consider inclusion . 10 . Participants follow Screening : QTcF interval ECG &gt; 500 msec . Participants QTcF &gt; 450 must discuss Sponsor Medical Monitor enrolment . Heart failure A personal family history congenital QT prolongation A history know , untreated , ongoing hypothyroidism A history ongoing bradyarrhythmia A history Torsade de Pointe 11 . Females positive pregnancy test Screening already know pregnant , breastfeeding , plan conceive child study within 6 month cessation treatment . Males plan conceive child study within 6 month cessation treatment . 12 . A peripheral neuropathy Grade 3 4 , accord DMID ( Appendix 2 ) . Or , participant Grade 1 2 neuropathy likely progress/worsen course study , opinion Investigator . Previous Concomitant Therapy 13 . Concomitant use Monoamine Oxidase Inhibitors ( MAOIs ) prior use within 2 week randomization . 14 . Concomitant use serotonergic antidepressant prior use within 3 day randomization Investigator foresee potential risk serotonin syndrome combine linezolid . 15 . Concomitant use drug know prolong QTc interval ( include , limited , amiodarone , bepridil , chloroquine , chlorpromazine , cisapride , cyclobenzaprine , clarithromycin , disopyramide , dofetilide , domperidone , droperidol , erythromycin , fluoroquinolones , halofantrine , haloperidol , ibutilide , levomethadyl , mesoridazine , methadone , pentamidine , pimozide , procainamide , quinidine , sotalol , sparfloxacin , thioridazine ) . 16 . Concomitant use drug know induce myelosuppression . 17 . Concomitant use drug substance know strong inhibitor inducer cytochrome P450 enzyme ( include limit efavirenz , quinidine , tyramine , ketoconazole , fluconazole , testosterone , quinine , gestodene , metyrapone , phenelzine , doxorubicin , troleandomycin , cyclobenzaprine , erythromycin , cocaine , furafylline , cimetidine , dextromethorphan ) . Exceptions may include use lopinavir/ritonavir regimen note section 5.3.3 . 18 . Participants receive 2 week bedaquiline , linezolid delamanid prior first dose IMP . 19 . Participants exist TB diagnosis ( diagnosis make &gt; 4 week prior screen ) HIV coinfection , must ART least 4 week prior screen . 20 . Participants newly diagnose tuberculosis HIV may enrol provided appropriate HIV therapy initiate participant receive least 2 week study medication . 21 . HIV infect participant : follow antiretroviral therapy use : zidovudine , stavudine , didanosine . The antiretroviral therapy ( ART ) booster cobicistat use . Please reference restriction Section 5.3.3 Antiretroviral Therapy , guidance ART treatment treatment period . Diagnostic Laboratory Abnormalities 22 . Participants follow toxicity Screening ( lab may repeat screen period ) define enhanced Division Microbiology Infectious Disease ( DMID ) adult toxicity table ( November 2007 ) : 1 . Viral load &gt; 1000 IU/ml ( Unless newly diagnose HIV yet ART otherwise qualify participation ) ; 2 . CD4+ count &lt; 100 cells/µL ( HIV positive participant ) ; 3 . Serum potassium less low limit normal laboratory ; 4 . Hemoglobin &lt; 9.0 g/dL ; 5 . Platelets &lt; 100,000/mm3 ; 6 . Absolute neutrophil count ( ANC ) &lt; 1500/ mm3 ; 7 . Aspartate aminotransferase ( AST ) Grade 3 great ( &gt; 3.0 x ULN ) exclude ; Results 1.5 x ULN 3 x ULN must discuss approve Sponsor Medical Monitor 8 . Alanine aminotransferase Grade 3 great ( &gt; 3.0 x ULN ) exclude ; Results 1.5 x ULN 3 x ULN must discuss approve Sponsor medical monitor ; 9 . Total bilirubin great 1.5 x ULN exclude ; 11.5 x ULN must discuss approve Sponsor Medical Monitor 10 . Direct bilirubin • Greater ULN exclude 11 . Serum creatinine level great 1.5 time upper limit normal 12 . Albumin &lt; 3.0 mg/dl All inclusion exclusion criterion must meet . If single variable/value outside range acceptability , multiple value close limit and/or whenever Investigator reason suspect might health problem ( TB ) , enrolment consider discuss case sponsor medical monitor .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Tuberculosis</keyword>
	<keyword>Multi Drug-Resistant Tuberculosis</keyword>
	<keyword>Extensively Drug-Resistant Tuberculosis</keyword>
	<keyword>Drug-Resistant Tuberculosis</keyword>
	<keyword>Pretomanid</keyword>
	<keyword>PA-824</keyword>
	<keyword>Bedaquiline</keyword>
	<keyword>Linezolid</keyword>
	<keyword>NC-007</keyword>
	<keyword>TB Alliance</keyword>
	<keyword>pre-XDR-TB</keyword>
</DOC>